ArticleCancers2025
The Role of MRI Radiomics Using T2-Weighted Images and the Apparent Diffusion Coefficient Map for Discriminating Between Warthin's Tumors and Malignant Parotid Gland Tumors.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesDifferentiating between benign and malignant parotid gland tumors (PGT) is essential for establishing the treatment strategy, which is greatly influenced by the tumor's histology. The objective of this study was to evaluate the role of MRI-based radiomics in the differentiation between Warthin's tumors (WT) and malignant tumors (MT), two entities that proved to present overlapping imaging features on conventional and functional MRI sequences.
methodsIn this retrospective study, a total of 106 PGT (66 WT, 40 MT) with confirmed histology were eligible for radiomic analysis, which were randomly split into a training group (79 PGT; 49 WT; 30 MT) and a testing group (27 PGT; 17 WT, 10 MT). The radiomic features were extracted from 3D segmentations of PGT performed on the following sequences: PROPELLER T2-weighted images and the ADC map, using a dedicated software. First- and second-order features were derived for each lesion, using original and filtered images.
resultsAfter employing several feature reduction techniques, including LASSO regression, three final radiomic parameters were identified to be the most significant in distinguishing between the two studied groups, with fair AUC values that ranged between 0.703 and 0.767. All three radiomic features were used to construct a Radiomic Score that presented the highest diagnostic performance in distinguishing between WT and MT, achieving an AUC of 0.785 in the training set, and 0.741 in the testing set.
conclusionsMRI-based radiomic features have the potential to serve as promising novel imaging biomarkers for discriminating between Warthin's tumors and malignant tumors in the parotid gland. Nevertheless, it is still to prove how radiomic features can consistently achieve higher diagnostic performance, and if they can outperform alternative imaging methods, ideally in larger, multicentric studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.